Share Name Share Symbol Market Type Share ISIN Share Description
Immupharma LSE:IMM London Ordinary Share GB0033711010 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +1.125p +2.39% 48.125p 47.25p 49.00p 48.00p 44.00p 46.00p 402,153 16:35:09
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.2 -6.3 -4.5 - 63.78

Immupharma Share Discussion Threads

Showing 8426 to 8449 of 8450 messages
Chat Pages: 338  337  336  335  334  333  332  331  330  329  328  327  Older
DateSubjectAuthorDiscuss
19/8/2017
12:56
Whatever, but I still believe IMM has the potential to be a big blockbuster. It may be taken over before it reaches its full potential but that doesn't really matter as long as 1) They have found cure for Lupozur over and above current offering - to increase the quality of patient's lives in a safer way 2)the shareholders value is realised. We all know IMM is in unique position to be granted special dispensation by the FDA a) to fast path Phase III b) Special Protocol Assessment for the trial. So far, and as far as I can tell (I am not expert in this field), nothing is announced to contradict their stated aims/objectives and the pending results. Thanks to someone here the recent response from IMM on a few questions was encouraging. I think share price will be well over a quid before the results, just on speculation alone. If trial results are positive then sky is the limit. I am a holder. GLA & DYOR.
divinessence
19/8/2017
07:47
Nothing to read into the latest RNS. It was a error on the PR team when Tim became chairman which has been rectified by a late Friday after hours RNS. The lateness or after hours RNS is significant as Companies use this tactic to bury "Bad News". There is no bad news on this issue.... just a PR error I believe.
flavio_monteiro
18/8/2017
19:45
s-k - disappointed to hear you believe in astrology - thought you were a bit more rational than that. There's an infinite possible set of trend lines that can be drawn on any chart, largely depending on the time scale chosen. Unless you set the selection rules in advance and stick to them, 'charting' is just a way of justifying one's own biases. Even in the chart you link, there's a very different result if you start at the left and continue to the right, rather than arbitrarily choosing to ignore the 2015 numbers because they don't give the outcome you're looking for. Similarly, if you'd plotted over 2017 only, it might well have looked as though the Lanstead deal was causing the price to become range-bound. Or even, if you start from spring 2017, that the price was coming off, the lack of news causing buyers to drift away. Or anything really, depending on what you want the result to be. I guess doing this charting stuff might be useful as a way of helping you understand your own prejudices, but as a means of predicting future prices, it's completely useless - white noise on the markets.
supernumerary
18/8/2017
19:36
All speculation but rather fun! Been an 'interesting' day. Lot's of lessons re nervous Pi's reacting to events and questions, answered by the company. Power of social media! As an investor, it's great to be able to air all views.
waterloo01
18/8/2017
19:19
See Rule 17 or paragraph (g) of Schedule 2 in http://www.londonstockexchange.com/companies-and-advisors/aim/advisers/aim-notices/aimrulesforcompaniesjan16.pdf However there is guidance notes for Schedule 2 on page 49 which says (g) Whilst directors are usually only required to disclose directorships held over the last five years, the requirements contained in (g)(iv)-(vii) which relate to bankruptcies, receiverships and liquidations are not limited to the last five years. Hence, I think there is an innocent enough explanation but the more interesting question is what triggered this check. The aim rules are from July 2016. Hopefully it is part of DD but let's wait and see
oilbagger
18/8/2017
19:01
For McCarthy appointment the RNS (30/9/2015) is below. It just lists companies where he was a director 5 years ago but mentions Alizyme in the introduction. Perhaps Alizyme wasn't mentioned because it was back in Dec 2009. Could be the AIM rule has changed or was interpreted incorrectly (was within 12 month of his appointment) Mr McCarthy has a 35 year international business career in high growth biotech, healthcare and technology companies. He is currently Chairman and Non-Executive Director for a number of biotech and healthcare related companies, including Incanthera, Harvard Healthcare and Expedeon Holdings. Mr McCarthy is also the former Chief Executive Officer and Finance Director of a number UK listed public and private companies, including Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, Mr McCarthy has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing. A Fellow of the Association of Chartered Certified Accountants, Mr McCarthy has an MBA from Cranfield School of Management. Commenting on Tim McCarthy's appointment, Dimitri Dimitrou, Chief Executive Officer, said: "We are delighted to have Tim join ImmuPharma as Chairman. This appointment represents a further strong addition to the Board. Tim's commercial and industry background together with capital markets experience will be extremely valuable as ImmuPharma progresses its lead compound, LupuzorTM, through its pivotal Phase III trial, as well as providing guidance on ImmuPharma's long term business strategy." Current Directorships Ark Analytics Solutions Limited BBN International Limited Dropped Limited Expedeon Holdings Limited Frangipani Dreams Limited Harvard Healthcare Limited Incanthera Limited Spear Therapeutics Limited Unnamed Limited Wise Old Owl Limited Directorships in the Last 5 years Retail Service Team Limited* *This company entered into a Creditors Voluntary Winding-up on 12th December 2013, 8 months after Mr McCarthy's resignation of directorship. It was dissolved on 4 June 2015. There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.
oilbagger
18/8/2017
18:53
Yes the info is freely available by a simple Google search Housekeeping?
pj 1
18/8/2017
18:52
For those who don't believe in charting...see where the share price bounced off today at the below link... hTTps://www.dropbox.com/s/ar22eng4079ysoh/IMM%20Chart.png?dl=0 Doesn't guarantee anything but can be a good guide. Bounced off the near 2 year uptrend today, keeping that uptrend in place. See the chart again. There is the gap at 40.8p, see the lower red line, but so long as the uptrend is not broken, it will not get there. I think it likely to get there if the uptrend is broken.
sicilian_kan
18/8/2017
18:48
The announcement in the RNS is not that important in itself (public knowledge and discussed here before - this should have been included when McCarthy was appointed in 2015 - just carelessness ) but I have to agree with waterloo1 - there is a possibility that Due Diligence (DD) as part of a deal or takeover has brought this up. Before everyone gets too exciting it might be just IMM advisors making sure everything is in good shape before negotiations begin.
oilbagger
18/8/2017
18:34
Is there a rule change for AIM and it had to be released?
barriew
18/8/2017
18:32
Divinessence - see the Rns that was released after hours today. Waterloo is speculating on the reason for releasing it at this time
homebrewruss
18/8/2017
18:25
Sorry guys what it is the DEAL? or What disclousure?
divinessence
18/8/2017
18:14
A DEAL!!!!!!!! ?
glennrcharles
18/8/2017
17:16
No worries. Odd timing re RNS and TM's roles back in 2009. Something come up in some DD and clearing the decks? Pure speculation on my part, but won't be funding so if is anything, is a deal being concluded?
waterloo01
18/8/2017
17:07
waterloo1 - apologies
oilbagger
18/8/2017
16:23
Great post People get carried away with over hype in all aspects and lose sight of why they invested in the first place Take a look back at prof muller presentation in June 2016 one very important comment made she dwelled on was KNOW LUPUS her team have spent the best part 12years investigating every aspect of lupus.They know this disease inside out I would suggest far more than anyother research organisations allso backed by one of the largest teams in Europe her own words.Im confident in what I've read and seen to believe this will be a once in a lifetime investment.
best1467
18/8/2017
15:17
In Phase 1 and 2B trials both anti-ds DNA antibodies and the cytokine IL10 were measured and changed in the patients who received Lupuzor thus proving it has a measurable biological effect.At the recent British Rheumatology AGM, Prof David Isenberg, the leading UK authority on SLE gave a talk on future therapeutic developments in the field, and spent considerably more time discussing Lupuzor and its mechanism of action than the alternatives. I thank Nobby for his efforts to provide balance to discussions on the future of this drug, but I bet David Isenberg has a better handle on developments in the field than most of the unnamed KOLs in FirstPharmas inaccessible article.
mcdermov
18/8/2017
14:55
A bit lame asking after the fact, but no problem. Was for public consumption.
waterloo01
18/8/2017
14:53
Waterloo1 - hope you don't mind me reproducing your post on lse
oilbagger
18/8/2017
13:58
Got close to filling the gap at 40p referred to by other posters... it didn't though so although recovery in share price this pm welcome it's unlikely to stick.
rollthedice
18/8/2017
13:55
Good to see the response from the company. Clearly they have not done a very good job in convincing the KOLs, who are the experts in the field, about the molecule. With regard to the dose comparison with anifrolumab, in the MUSE trial both the 300mg dose and 1000mg dose were statistically significantly different from placebo at day 169 and 365. The higher dose was better at the former time point and the lower dose at the latter. So it is not quite right to compare the anifrolumab data with the Lupuzor phase II data with regard to the dose effect. GLA Nobby
nobbygnome
18/8/2017
13:38
Bookbroker my ref was to a investment remark made by Warren buffet on the significance of timing when making great returns,shame how the mind works
best1467
18/8/2017
13:36
Time to buy the fear!
mcdermov
18/8/2017
13:23
Thanks Waterloo
sicilian_kan
Chat Pages: 338  337  336  335  334  333  332  331  330  329  328  327  Older
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:30 V: D:20170819 18:51:19